Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Japan.
Department of Surgery, Monbetsu General Hospital, Monbetsu, Japan.
Anticancer Res. 2024 Sep;44(9):4039-4047. doi: 10.21873/anticanres.17233.
BACKGROUND/AIM: Various biomarkers are utilized in the field of breast cancer. Human lymphocyte antigen (HLA) class I molecules have a critical role in cancer immune surveillance. Therefore, this study aimed to assess the HLA class I expression and analyze the correlation with clinicopathologic factors in breast cancer.
We investigated the clinical pathology archives of 150 consecutive patients with breast cancer who underwent a curative operation at the Sapporo Medical University, Japan, from January 2012 to December 2014. Immunohistochemical staining was used to evaluate HLA class I expression and CD8-positive T cell infiltration. The Pearson χ test was used to assess HLA class I expression level and clinicopathological parameters. The Kaplan-Meier method was used to evaluate survival and the log-rank test to analyze the differences between survival curves.
Patients with dull/negative HLA class I had significantly poor disease-free survival (DFS) compared with those with positive HLA class I (p=0.0073). Univariate analyses revealed that pT, pN, positive lymphatic invasion, and dull/negative HLA class I were significantly associated with DFS. Multivariate analyses revealed dull/negative HLA class I as an independent poor prognostic factor (hazard ratio=2.75, 95% confidence interval=1.30-5.80, p=0.008).
HLA class I expression level may have a very sensitive prognostic effect on patients with breast cancer.
背景/目的：在乳腺癌领域中应用了各种生物标志物。人类淋巴细胞抗原（HLA）I 类分子在癌症免疫监视中起着关键作用。因此，本研究旨在评估 HLA I 类分子的表达，并分析其与乳腺癌临床病理因素的相关性。
我们研究了日本札幌医科大学 2012 年 1 月至 2014 年 12 月期间连续 150 例接受根治性手术的乳腺癌患者的临床病理档案。采用免疫组织化学染色法评估 HLA I 类分子的表达和 CD8 阳性 T 细胞浸润情况。采用 Pearson χ检验评估 HLA I 类分子表达水平与临床病理参数的相关性。采用 Kaplan-Meier 法评估生存情况，采用对数秩检验分析生存曲线之间的差异。
HLA I 类分子表达阴性/不典型的患者无病生存期（DFS）显著差于 HLA I 类分子表达阳性的患者（p=0.0073）。单因素分析显示，pT、pN、阳性淋巴管浸润和 HLA I 类分子表达阴性/不典型与 DFS 显著相关。多因素分析显示，HLA I 类分子表达阴性/不典型是独立的不良预后因素（风险比=2.75，95%置信区间=1.30-5.80，p=0.008）。
HLA I 类分子表达水平可能对乳腺癌患者具有非常敏感的预后作用。
